Construction of CTLA-4-Ig Fusion Gene in pBudCE4.1 Expression Vector.

Mahsa Yazdanpanah-Samani, Elham Mahmoudi Maymand, Tayebeh Jahangeerfam, Abbas Ghaderi

Open access · greenAbstract read

In one paragraph

Article in Avicenna journal of medical biotechnology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact, top 96% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mahsa Yazdanpanah-SamaniShiraz Institute for Cancer Research, Faculty of Medicine, Shiraz University of Medical Science, Shiraz, Iran.

Elham Mahmoudi MaymandShiraz Institute for Cancer Research, Faculty of Medicine, Shiraz University of Medical Science, Shiraz, Iran.

Tayebeh JahangeerfamDepartment of Immunology, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Abbas GhaderiShiraz Institute for Cancer Research, Faculty of Medicine, Shiraz University of Medical Science, Shiraz, Iran ; Department of Immunology, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Shiraz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCTLA-4 inhibitory signals prevent cell cycle progression and IL-2 production, leading to a halt on an ongoing immune response. CTLA4-Ig fusion proteins contain the extracellular domain of CTLA-4 and Fc fragment of human IgG antibody. In this study we aimed to fuse the ctla-4 gene encoding the extracellular domain of CTLA-4 molecule with igg1 gene encoding Fc region of human IgG.

methodsAfter primer design, PCR reaction was performed using pfu polymerase enzyme and specific primers. PCR amplified fragment was ligated into the vector containing the human igg1 gene. The resulting fusion fragment of ctla-4 and human igg1 genes was ligated to pBudCE4.1 expression vector.

resultsExtracellular domain of ctla-4 gene was ligated to igg1 gene and then ctla4-ig fragment was cloned into pBudCE4.1 vector. Construction of the expression vector was confirmed by restriction pattern analysis and sequencing.

conclusionBy confirming the construct, in the next step, the recombinant DNA will be used to produce CTLA4-Ig recombinant protein for the clinical uses.

Indexed as

AbataceptCTLA-4 antigenCTLA4-IgRecombinant DNA

Identifiers

PMID26605013

PMCPMC4629461

OpenAlexW1218850682

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.